Market cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-23 Mln
-
ROE
-6.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-24.3
-
Face value
--
-
Shares outstanding
10,704,800
10 Years Aggregate
CFO
$-300.43 Mln
EBITDA
$-326.53 Mln
Net Profit
$-260.61 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ContraFect Corp (CFRX)
| -9.7 | -17.9 | -88.8 | -99.5 | -96.0 | -85.0 | -- |
|
BSE Sensex*
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
ContraFect Corp (CFRX)
| -99.6 | -96.3 | -47.9 | -18.6 | -59.4 | 51.1 | -42.3 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ContraFect Corp (CFRX)
|
0.0 | 0.5 | 0.0 | -22.0 | -- | -- | -- | 0.4 |
| 0.0 | 3.0 | 7.0 | -81.2 | -1,216.8 | -- | -- | 1.7 | |
| 31.2 | 8,724.2 | 287.6 | -73.1 | -27.4 | -21.4 | -- | 15.5 | |
| 0.0 | 5.8 | 21.0 | -96.1 | -338.3 | -- | -- | 18.5 | |
| 0.0 | -- | 481.6 | -1,440.6 | -91.5 | -- | -- | 0.0 |
Shareholding Pattern
View DetailsAbout ContraFect Corp (CFRX)
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program... includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Chairman, CEO & Pres
Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.
-
Chairman, CEO & Pres
Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.
-
Headquarters
Yonkers, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ContraFect Corp (CFRX)
What is the current share price of ContraFect Corp (CFRX) Today?
The share price of ContraFect Corp (CFRX) is $0.03 (NASDAQ) as of 07-Feb-2024 09:30 EDT. ContraFect Corp (CFRX) has given a return of -95.98% in the last 3 years.
What is the current PB & PE ratio of ContraFect Corp (CFRX)?
Since, TTM earnings of ContraFect Corp (CFRX) is negative, P/E ratio is not available.
The P/B ratio of ContraFect Corp (CFRX) is 0.44 times as on 07-Feb-2024, a 90 discount to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.19
|
0.03
|
|
2020
|
-0.06
|
0.14
|
|
2019
|
-0.01
|
0.00
|
|
2018
|
0.00
|
0.03
|
What is the 52 Week High and Low of ContraFect Corp (CFRX)?
The 52-week high and low of ContraFect Corp (CFRX) are Rs -- and Rs -- as of 07-Jun-2026.
What is the market cap of ContraFect Corp (CFRX)?
ContraFect Corp (CFRX) has a market capitalisation of $ 1 Mln as on 07-Feb-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in ContraFect Corp (CFRX)?
Before investing in ContraFect Corp (CFRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.